



NDA 21976/S-29  
NDA 202895/S-6

## SUPPLEMENT APPROVAL

Janssen Products, L.P.  
Attention: Karen Gerry, BSc  
Manager, Global Regulatory Affairs  
1125 Trenton-Harbourton Rd  
Titusville, NJ 08560

Dear Ms. Gerry:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received August 3, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Prezista<sup>®</sup> (darunavir) tablets, 75 mg, 150 mg, 400 mg, 600 mg, and 800 mg, and Prezista<sup>®</sup> (darunavir) oral suspension, 100 mg/mL.

We acknowledge receipt of your amendments dated:

August 16, 2012  
August 27, 2012  
September 5, 2012  
October 5, 2012  
November 2, 2012  
November 15, 2012  
November 21, 2012

November 28, 2012  
December 6, 2012  
December 17, 2012  
December 18, 2012  
January 7, 2013  
January 24, 2013  
January 29, 2013.

These “Prior Approval” supplemental new drug applications propose to update labeling with once daily dosing in:

- HIV-1 infected, treatment-naïve pediatric patients 3 to less than 12 years of age, and
- HIV-1 infected, treatment-experienced pediatric patients 3 to less than 18 years of age with no darunavir resistance associated substitutions.

These changes are based on pharmacokinetic modeling and simulation data that includes the darunavir/ritonavir pediatric clinical trials TMC114-C230, TMC114-C212, and TMC114-228.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Instruction for Use), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to 3 years because there is evidence strongly suggesting that the drug product would be unsafe in this pediatric group. This decision is based on the results of juvenile rat toxicology studies that provide evidence of a potential safety risk as a result of drug-brain accumulation.

We note that you have fulfilled the pediatric study requirement for ages 3 to less than 18 years for this application.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Linda C. Onaga, Regulatory Project Manager, at (301) 796-0759 or (301) 796-1500.

Sincerely,

*{See appended electronic signature page}*

Debra Birnkrant, MD  
Director  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JEFFREY S MURRAY  
02/01/2013